XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $1.44M invested in XTL Biopharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
69% more capital invested
Capital invested by funds: $848K → $1.44M (+$589K)
0.52% more ownership
Funds ownership: 8.24% → 8.76% (+0.52%)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$46.3K |
| 2 |
Morgan Stanley
New York
|
+$22.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2K |
XTLB Hedge Fund Activity: Q4 2020 in Review
4 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2020, worth a combined $1.44M — up 69% from $848K a quarter earlier.
Fund positioning in XTLB was balanced in Q4 2020: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $46.3K. The largest seller was UBS Group, exiting entirely with an estimated $2K sold.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $1.44M of XTL Biopharmaceuticals stock for Q4 2020, up 69% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q4 2020 and 1 closed out, a net change of 0 holders.
- The largest XTL Biopharmaceuticals buyer in Q4 2020 was Renaissance Technologies, an estimated $46.3K added.
- The largest XTL Biopharmaceuticals seller in Q4 2020 was UBS Group, an estimated $2K sold.
Based on aggregated 13F filings for Q4 2020.